Buy Vitrakvi (Larotrectinib) Online in India – Complete Guide

Introduction to Vitrakvi (Larotrectinib)

What is Vitrakvi?

Vitrakvi is the brand name for larotrectinib. It is a highly selective medication used to treat various types of cancer. It belongs to a class of drugs known as kinase inhibitors.

Understanding Larotrectinib

How it works in the body - Larotrectinib functions by inhibiting tropomyosin receptor kinases (TRK), specifically the TrkA, TrkB, and TrkC proteins. These proteins are encoded by the genes NTRK1, NTRK2, and NTRK3. When these genes fuse with other unrelated genes, they create TRK fusion proteins that act as oncogenic drivers, causing cancer cells to grow and survive uncontrollably. Larotrectinib blocks these signals to stop tumor progression.

Targeted cancer therapy explained simply- Unlike traditional chemotherapy that affects many types of cells, larotrectinib is a targeted therapy. It targets a specific genetic mutation (NTRK gene fusion) regardless of where the cancer originated in the body (such as the lungs, thyroid, or colon).

Conditions Treated by Vitrakvi

NTRK gene fusion cancers

Vitrakvi is specifically indicated for adult and paediatric patients whose solid tumors test positive for an NTRK gene fusion without a known resistance mutation. It is generally used when the cancer is locally advanced, metastatic, or when surgery would cause severe complications, and there are no other satisfactory treatments.

Types of tumors treated

Because it is tumor-agnostic, it can be used for a wide range of cancers, with differing rates of success in anti-tumour responses, including:

Soft tissue sarcoma and infantile fibrosarcoma.

Thyroid cancer and salivary gland tumors.

Lung, colon, and breast cancers.

Primary CNS tumors (brain and spinal cord) and brain metastases.

Gastrointestinal stromal tumors (GIST) and biliary tract cancers.

Who Should Take Vitrakvi?

Eligibility criteria

Eligibility is based on the presence of an NTRK gene fusion rather than the patient's age or tumor type. It is used for patients who have progressed following previous treatments or have no other acceptable options.

Doctor’s evaluation factors

A physician must select patients for this therapy based on an FDA-approved diagnostic test that confirms the NTRK gene fusion status. Testing methods include next-generation sequencing (NGS), fluorescence in situ hybridization (FISH), or immunohistochemistry (IHC).

Dosage and Forms Available

i. Capsules and Oral Solution

Vitrakvi is available in two main forms for oral use:

Capsules: Provided in strengths of 25 mg and 100 mg.

Oral Solution: Available as a 20 mg/mL solution, which is often preferred for paediatric use or patients who cannot swallow capsules.

ii. Recommended dosage

The standard dosage for adults and paediatric patients with a body surface area of at least 1.0 m² is 100 mg taken twice daily. For children with a body surface area less than 1.0 m², the dosage is 100 mg/m² twice daily. Treatment continues until the disease progresses or side effects become unacceptable.

How to Take Vitrakvi Properly

i. Daily usage tips

Vitrakvi should be taken two times a day, with or without food. Capsules must be swallowed whole with water and should not be chewed or crushed. If using the oral solution, it must be measured exactly using an oral syringe.

ii. Missed dose guidelines

If you miss a dose, take it as soon as you remember. However, if the next scheduled dose is due within 6 hours, skip the missed dose and resume your regular schedule. Do not take two doses simultaneously to make up for a missed one.

Benefits of Vitrakvi Treatment

Effectiveness in targeted therapy

Clinical trials have shown that Vitrakvi is highly effective, with an overall response rate of approximately 75% to 80% across different tumor types. Many patients experience rapid and durable responses, with some responses lasting over two years.

Quality of life improvements

While the primary focus of studies is tumor response, quality of life was tracked as a secondary or exploratory endpoint in several trials, suggesting potential benefits for patient well-being.

Possible Side Effects

1. Common side effects

The most frequent side effects (occurring in 20% or more of patients) include:

i. Fatigue and tiredness.

ii. Nausea, vomiting, constipation, or diarrhea.

iii. Dizziness and musculoskeletal pain.

iv. Laboratory abnormalities, such as anemia and increased liver enzymes (AST and ALT).

2. Serious side effects

Serious risks that require medical attention include:

i. Central Nervous System (CNS) Effects: Dizziness, confusion, memory impairment, and mood changes.

ii. Skeletal Fractures: Increased risk of bone fractures, often associated with minimal trauma.

iii. Hepatotoxicity: Potential for drug-induced liver injury.

iv. Embryo-Fetal Toxicity: Can cause harm to an unborn baby if taken during pregnancy.

Safety Precautions

1. Before starting treatment

Inform your doctor if you have liver problems, neurological issues, or are pregnant or planning to become pregnant. Females of reproductive potential should have a pregnancy test before starting and must use effective contraception during treatment and for one week after the final dose. Breastfeeding is not recommended during treatment.

2. During treatment monitoring

Your doctor will perform liver function tests (ALT, AST, bilirubin) every 2 weeks for the first month of treatment and then monthly thereafter. Monitoring for neurological symptoms and signs of bone pain or fractures is also necessary.

Drug Interactions

Medicines to avoid

Certain substances can change efficacy and effectiveness of Vitrakvi or increase side effects:

- Avoid strong CYP3A4 inhibitors (e.g., certain antifungals) and grapefruit or grapefruit juice.

- Avoid strong CYP3A4 inducers (e.g., rifampin) and St. John’s wort, as they can make the drug less effective.

Lifestyle considerations

Because Vitrakvi can cause dizziness and cognitive impairment, patients should not drive or operate heavy machinery until they know how the medication affects them.

Buying Vitrakvi Online in India

Availability challenges

Why patients import it

Patients often seek to import specialized drugs like Vitrakvi when they have rare genetic mutations (like NTRK fusions) and no satisfactory standard treatment options are available locally.

Larotrectinib Price in India

Cost factors

Larotrectinib is not currently registered in India and is therefore not available through regular pharmacies or standard distribution channels. As this is a prescription-only medication, for those interested in accessing larotrectinib in India,  a price quotation is shared after reviewing valid medical documents and a doctor’s prescription. For the most up-to-date pricing and supply details, patients may contact our support team. 

Note that the price of Vitrakvi in India may differ based on factors such as market demand, supplier access, import regulations, and availability from international manufacturers. The total cost may also depend on shipping charges, origin country, documentation fees, and currency exchange rates. Pricing may also be affected by local taxes (GST) and any revisions in company or distributor pricing policies.

Ways to reduce cost

We can negotiate reimbursement and standard price points of such products. Our patient assistance programs may help to reduce costs in India. We assist patients in India with the safe and lawful access to larotrectinib through the Named Patient Supply (NPS) program, ensuring compliance with all import regulations. Our services include document verification, import coordination, and doorstep delivery of the medicine.

How to Choose a Reliable Supplier

Key things to check

Avoiding fake medicines

Standard medical precautions advise purchasing only from licensed pharmacies or authorized importers to avoid counterfeit products. 

Storage and Handling

Proper storage conditions

1. Capsules: Store at room temperature between 20°C to 25°C (68°F to 77°F).
2. Oral Solution: Must be refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze.

Safety tips at home

Keep all forms of the medicine out of reach of children. For the oral solution, discard any unused portion 90 days after first opening the bottle.

Tips for Patients and Caregivers

Managing treatment journey

Caregivers should help monitor the patient for neurological changes and ensure they attend all scheduled liver function tests. If vomiting occurs after a dose, do not repeat the dose; simply wait until the next scheduled time.

Emotional and physical support

Because mood disorders such as anxiety, depression, and irritability can occur in up to 14% of patients, providing emotional support and reporting changes in mental health to a doctor is essential.

Conclusion

Vitrakvi (larotrectinib) represents a major advancement in precision oncology, offering a highly effective, targeted option for patients with NTRK gene fusion-positive tumors. Successful treatment requires careful genetic testing, consistent monitoring of liver and brain health, and strict adherence to dosage and safety guidelines.